Research Article
Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice
Table 1
Summary of experimental design: histopathology phase.
| | Test or control article | Total weight administered | Number of doses | Days on test | Number of animals |
| | Saline | 0.005 mL | 1 | 4 | 5♂, 5♀ | | Long acting drug powder | 3 mg | 1 | 4 | 5♂, 5♀ | | Long acting drug powder | 15 mg | 1 | 4 | 5♂, 5♀ | | Saline | 0.015 mL | 3 | 12 | 5♂, 5♀ | | Long acting drug powder | 9 mg | 3 | 12 | 5♂, 5♀ | | Long acting drug powder | 45 mg | 3 | 12 | 5♂, 5♀ |
|
|
